SLC5A2 and type 2 diabetes mellitus: Recently, clinical evidence has suggested that SGLT2 inhibitors have hepatoprotective effects, reducing the liver fat mass and improving the liver enzymes in patients with type 2 diabetes and MASLD [11–13].